| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.4K | 0.6% | 10.8% |
| Total Income | 1.4K | 0.6% | 10.8% |
| Expenditure | 931.60 | 0.1% | 7.6% |
| PBT | 502.31 | 1.2% | 20.3% |
| Net Profit | 398.73 | 1.6% | 9.2% |
| OPM | 34.92% | 0.36pp | 1.92pp |
| NPM | 27.86% | 0.26pp | 0.40pp |
| EPS | 2.74 | 1.9% | 10.0% |
Resmed Reports Q3 FY26 Revenue of $1.4 Billion, Up 11% YoY, Non-GAAP EPS Up 21%
01 May 2026 · 1 May, 1:51 am
Summary
Resmed Inc. announced strong results for the third quarter of fiscal year 2026, with revenue climbing 11% to $1.4 billion, or 8% on a constant currency basis. The company achieved significant margin expansion, with GAAP gross margin up 290 basis points to 62.2% and non-GAAP gross margin reaching 62.8%. This performance translated into a 21% increase in non-GAAP diluted earnings per share to $2.86. Chairman and CEO Mick Farrell highlighted the continued strength of the global business, driven by demand for market-leading products and disciplined strategy execution, expressing focus on expanding access to care and delivering further profitable growth.
Key Highlights
- 1
Resmed Inc. reported a robust 11% increase in revenue to $1.4 billion for the third quarter of fiscal year 2026, or 8% on a constant currency basis.
- 2
GAAP gross margin expanded by 290 basis points to 62.2%, while non-GAAP gross margin also rose by 290 basis points to 62.8% for the quarter.
- 3
GAAP income from operations grew by 17%, and non-GAAP income from operations increased by 18% during Q3 FY26.
- 4
Non-GAAP diluted earnings per share saw a significant 21% increase, reaching $2.86, driven by strong sales growth and improved gross margin.
- 5
The company generated $554 million in operating cash flow for the quarter and returned $262 million to shareholders through share repurchases and dividends.
- 6
Resmed announced a quarterly cash dividend of US $0.60 per share, payable on June 18, 2026.
- 7
The company is expanding its U.S. operations with a new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027, and launched the AirTouch F30i Comfort full face mask in the U.S.
Management Comments
Mick Farrell
Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy. Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home. As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.
Informational and educational content only. Not investment advice.